Skip to main content
PMC home page
BMC Cancer logoLink to BMC Cancer
. 2016 Jan 11;16:8. doi: 10.1186/s12885-015-2046-7

Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models

Giovanni Luca Gravina 1, Andrea Mancini 1, Patrizia Sanita 1, Flora Vitale 1, Francesco Marampon 1, Luca Ventura 2, Yosef Landesman 3, Dilara McCauley 3, Michael Kauffman 3, Sharon Shacham 3, Claudio Festuccia 1,✉
PMCID: PMC4707722  PMID: 26753765

Unfortunately, the original version of this article [1] contained a mistake. The word ‘survivin’ in the title was incorrectly included as ‘surviving’. The title has been corrected above and in the original article.

Footnotes

The online version of the original article can be found under doi:10.1186/s12885-015-1936-z.

Reference

  • 1.Gravina G, Mancini A, Sanita P, Vitale F, Marampon F, Ventura L. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models. BMC Cancer. 2015;15:941. doi: 10.1186/s12885-015-1936-z. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMC Cancer are provided here courtesy of BMC

RESOURCES